



IFW

Attorney Docket No. 37991-0032

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant(s): Pascal BIGEY et al. Confirmation No.: 3543  
Appl. No.: 10/506,766 Examiner: Unassigned  
Filing Date: November 12, 2004 Art Unit: 1645  
Title: DNA DEMETHYLASE ANTISENSE AND CHEMOTHERAPY  
COMBINATION

**INFORMATION DISCLOSURE STATEMENT  
UNDER 37 CFR §1.56 and 37 CFR §1.97**

Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

Sir:

Submitted herewith on Form PTO/SB/08A is a listing of documents known to Applicants in order to comply with Applicant's duty of disclosure pursuant to 37 C.F.R. §1.56 and §1.97. A copy of each of the listed documents are being submitted to comply with the provisions of 37 C.F.R. §1.97-1.99.

The submission of any document herewith, which is not a statutory bar, is not intended as an admission that such document constitutes prior art against the claims of the present application or is considered to be material to patentability as defined in 37 C.F.R. §1.56(b). Applicants do not waive any rights to take any action which would be appropriate to antedate or otherwise remove as a competent reference any document which is determined to be a *prima facie* prior art reference against the claims of the present application.

**TIMING/FEE**

The instant Information Disclosure Statement is being filed in compliance with 37 CFR §1.97(b) prior to the mailing date of the first official action, therefore, no fee is required in connection with its filing. However, the Commissioner is hereby authorized to charge any deficiency or to credit any overpayment to Deposit Account No. 08-1641.

RELEVANCE

The documents came to the Applicants' attention during a search of the corresponding international application. A copy of the International Search Report setting forth the portion of each reference considered relevant by the examiner is attached.

Applicants respectfully request that the listed documents be considered by the Examiner and be made of record in the present application and that an initialed copy of Form PTO/SB/08A be returned in accordance with M.P.E.P. §609.

Respectfully submitted,


Date: December 1, 2005

By Patricia D. Granados

HELLER EHRMAN LLP  
1717 Rhode Island Avenue, NW  
Washington, DC 20036  
Telephone: (202) 912-2142  
Facsimile: (202) 912-2020

Patricia D. Granados  
Attorney for Applicants  
Registration No. 33,683  
Customer No. 26633

PTO/SB/08A (10-01)



Please type a plus sign (+) inside this box ☐ PTO/SB/08A (08-00)

Approved for use through 10/31/2002. OMB 0651-0031  
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

<b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  (use as many sheets as necessary)		<b>Complete if Known</b>			
		Application Number	10/506,766		
		Filing Date	November 12, 2004		
		First Named Inventor	Pascal BIGEY et al.		
		Group Art Unit	1645		
		Examiner Name	Unassigned		
Sheet	2	of	2	Attorney Docket Number	37991-0032

OTHER PRIOR ART -- NON PATENT LITERATURE DOCUMENTS			
Examiner Initials *	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>2</sup>
	A04	SANJOY K. BHATTACHARYA et al., "A mammalian protein with specific demethylase activity for mCpG DNA", Nature, February 18, 1999, pp. 579-583, Vol. 397	
	A05	MOSHE SZYF, "The DNA Methylation Machinery as a Therapeutic Target", Current Drug Targets, 2000, pp. 101-118, Vol. 1	
	A06	ANDREW SLACK et al., "Antisense MBD2 gene therapy inhibits tumorigenesis", The Journal of Gene Medicine", 2002, pp. 381-389, Vol. 4	
	A07	MARIE-AGNES IVANOV et al., "Enhanced antitumor activity of a combination of MBD2-antisense electrotransfer gene therapy and bleomycin electrochemotherapy", The Journal of Gene Medicine, 2003, pp. 893-899, Vol. 5	

Examiner Signature		Date Considered	
-----------------------	--	--------------------	--

\* EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Unique citation designation number. <sup>2</sup> Applicant is to place a check mark here if English language Translation is attached.